BJH - volume 7, issue Abstract Book BHS, january 2016
M. Van Damme , E. Crompot , N. Meuleman MD, PhD, P. Mineur MD, D. Bron MD, PhD, L. Lagneaux , B. Stamatopoulos
BJH - volume 7, issue Abstract Book BHS, january 2016
S. Dubruille PhD, Y. Libert PhD, M. Roos , S. Vandenbossche , A. Collard , N. Meuleman MD, PhD, M. Maerevoet MD, A. Etienne , C. Reynaert , D. Razavi MD, PhD, D. Bron MD, PhD
BJH - volume 6, issue 5, december 2015
K. Beel MD, PhD, M.C. Vekemans MD, G. Bries MD, PhD, J. Caers MD, PhD, B. De Pryck MD, K. Fostier MD, A. Kentos MD, PhD, N. Meuleman MD, PhD, P. Mineur MD, I. Van de Broek MD, PhD, K.L. Wu MD, PhD, C. Doyen MD, M. Delforge MD, PhD
Immunoglobulin light chain amyloidosis is a clonal plasma cell dyscrasia, historically associated with a very poor prognosis. Prompt diagnosis is critical to preserve organ function and improve survival in immunoglobulin light chain amyloidosis patients. The severity of cardiac involvement and response to treatment are the most important prognostic factors. Serum free light chain ratio and cardiac biomarkers troponin T and N-terminal pro-brain natriuretic peptide are powerful tools for the evaluation of prognosis and treatment response. Historically, treatment with autologous stem cell transplantation appears to offer a survival benefit, but is only an option in a minority of patients. IMiDs, and especially proteasome inhibitors, have shown promising activity in immunoglobulin light chain amyloidosis. Supportive care should be integrated in the treatment plan and requires a multidisciplinary approach. These guidelines summarise a consensus of the myeloma subcommittee of the Belgian Hematological Society on diagnosis, cytoreductive and supportive treatment of immunoglobulin light chain amyloidosis, based on an extended review of the literature. Where applicable, comments were added with respect to the Belgian reimbursement modalities.
(BELG J HEMATOL 2015;6(5):187–94)
Read moreBJH - volume 6, issue 1, march 2015
M. Maerevoet MD, J. Vouriot MD, N. Meuleman MD, PhD, D. Bron MD, PhD
Diffuse large B-cell lymphoma is a frequent pathology in older individuals, and though curable by R-CHOP 21, treatment toxicity increases in frail patients. Therefore, therapeutic choices have to take into account Comprehensive Geriatric Assessment in addition to Performance Status, but reliable and standardised clinical decision-making tools are sorely lacking. However, Mabthera-containing treatments adapted for frail patients and co-morbidities can be used with a satisfactory survival rate at two years. Nevertheless, the main cause of death remains disease progression.
(BELG J HEMATOL 2014;6(1):4–9)
Read moreBJH - volume 6, issue Abstract Book BHS, january 2015
H.R. Kourie , J. Nguyen , X. Wang , T. Gil , R. Dewind , P. Lewalle MD, PhD, N. Meuleman MD, PhD, D. Bron MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
G. Claes MD, D. Bron MD, PhD, M. Maerevoet MD, S. Benghiat MD, PhD, V. De Wilde MD, PhD, B. Bailly MD, N. Istaces , J. Brauner MD, O. Pradier MD, PhD, N. Meuleman MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
E. Crompot , M. Van Damme , H. Duvillier , K. Pieters , P. Mineur MD, N. Meuleman MD, PhD, D. Bron MD, PhD, L.L. Lagneaux , B. Stamatopoulous
Top
